Skip to content
MARKETS / NASDAQ / CTSO
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Cytosorbents Corp. CTSO

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$37.1M
▲ 4.1% YoY
$-8.2M
$-12.5M
In brief

What this company does

CytoSorbents’ lead product, CytoSorb, is approved in the European Union and distributed in more than 70 countries worldwide, with more than 300,000 devices used cumulatively to date. As of the issuance date of its Annual Report on Form 10-K, CytoSorbents had 129 employees. In the U.S. and Canada, CytoSorbents is developing the DrugSorb-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. CytoSorbents' executive offices are located at 305 College Road East, Princeton, New Jersey 08540.

Written from the business description in CYTOSORBENTS CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
USD 37.1M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 37.1 · Net income -8.2
20M40M-20M2007201020132016201920222025
Compound annual growth
+2.2%
−2.0%
+22.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −2.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−22 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -39.8% · Net -22.1%
-5000%-10000%-15000%2007201020132016201920222025
ROE
FY2025 · ROE -96.4%
-100%-200%2007201020132016201920222025

Each USD of equity lost 96 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -12.5
-20M2007201020132016201920222025

Total assetsUSD 44.2M
EquityUSD 5.9M
CashUSD 6.2M
Gross debtUSD 16.7M
Net debtUSD 10.4M
Current ratio2.13×

Net debt stands at 176% of equity.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0····
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0···
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
Income tax $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·····
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0···
EPS, diluted $−0.13−0.38−0.65−0.75−0.57−0.20−0.60−0.56−0.32−0.46−0.38−1.29−0.75−0.03−0.05−0.05···
Dividend / sh $···················
Payout %···················
ROE %−96.4−119.8−99.4−67.0−34.6−19.0−189.3−126.6−145.9−210.4−112.9········
Shares out B0.060.050.050.040.040.040.030.030.030.030.030.020.010.210.180.12···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 81 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 14 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image